Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function

Guerard W. Byrne, Johannes M. Schirmer, David N. Fass, Sumeet S. Teotia, Walter K. Kremers, Hui Xu, Bashoo Naziruddin, Henry D. Tazelaar, John S. Logan, Christopher G A McGregor

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Microvascular thrombosis is a prominent feature in cardiac delayed xenograft rejection (DXR). We investigated the impact of warfarin or low-molecular-weight heparin (LMWH) anti-coagulation on xenograft function using a heterotopic pig-to-primate model. Donor hearts were from CD46 transgenic pigs and baboon immunosuppression included tacrolimus, sirolimus, anti-CD20 and TPC, an α-galactosyl-polyethylene glycol conjugate. Three groups of animals were studied. Group 1 (n = 9) was treated with warfarin. Group 2 (n = 13) with LMWH and Group 3, received no anticoagulant drugs. The median duration of xenograft function was 20 days (range 3-62 days), 18 days (range 5-109 days) and 15 days (range 4-53 days) in Groups 1 to 3 respectively. Anti-coagulation achieved the targeted international normalized prothrombin ratio (INR) and anti-factor Xa levels consistent with effective in vivo therapy yet, no significant impact on median xenograft function was observed. At rejection, a similar histology of thrombosis and ischemia was apparent in each group and the levels of fibrin deposition and platelet thrombi in rejected tissue was the same. Anti-coagulation with warfarin or LMWH did not have a significant impact on the onset of DXR and microvascular thrombosis. However, a role for specific anticoagulant strategies to achieve long-term xenograft function cannot be excluded.

Original languageEnglish (US)
Pages (from-to)1011-1020
Number of pages10
JournalAmerican Journal of Transplantation
Volume5
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Low Molecular Weight Heparin
Warfarin
Heterografts
Primates
Swine
Thrombosis
Anticoagulants
Therapeutics
Factor Xa
International Normalized Ratio
Papio
Prothrombin
Tacrolimus
Sirolimus
Fibrin
Immunosuppression
Histology
Blood Platelets
Ischemia

Keywords

  • Antibody
  • Anticoagulation
  • Cardiac
  • Non-Gal
  • Thrombosis
  • Xenotransplantation

ASJC Scopus subject areas

  • Immunology

Cite this

Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. / Byrne, Guerard W.; Schirmer, Johannes M.; Fass, David N.; Teotia, Sumeet S.; Kremers, Walter K.; Xu, Hui; Naziruddin, Bashoo; Tazelaar, Henry D.; Logan, John S.; McGregor, Christopher G A.

In: American Journal of Transplantation, Vol. 5, No. 5, 05.2005, p. 1011-1020.

Research output: Contribution to journalArticle

Byrne, GW, Schirmer, JM, Fass, DN, Teotia, SS, Kremers, WK, Xu, H, Naziruddin, B, Tazelaar, HD, Logan, JS & McGregor, CGA 2005, 'Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function', American Journal of Transplantation, vol. 5, no. 5, pp. 1011-1020. https://doi.org/10.1111/j.1600-6143.2005.00792.x
Byrne, Guerard W. ; Schirmer, Johannes M. ; Fass, David N. ; Teotia, Sumeet S. ; Kremers, Walter K. ; Xu, Hui ; Naziruddin, Bashoo ; Tazelaar, Henry D. ; Logan, John S. ; McGregor, Christopher G A. / Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. In: American Journal of Transplantation. 2005 ; Vol. 5, No. 5. pp. 1011-1020.
@article{310bafa6c4854124ae3e5fb3aa9d894d,
title = "Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function",
abstract = "Microvascular thrombosis is a prominent feature in cardiac delayed xenograft rejection (DXR). We investigated the impact of warfarin or low-molecular-weight heparin (LMWH) anti-coagulation on xenograft function using a heterotopic pig-to-primate model. Donor hearts were from CD46 transgenic pigs and baboon immunosuppression included tacrolimus, sirolimus, anti-CD20 and TPC, an α-galactosyl-polyethylene glycol conjugate. Three groups of animals were studied. Group 1 (n = 9) was treated with warfarin. Group 2 (n = 13) with LMWH and Group 3, received no anticoagulant drugs. The median duration of xenograft function was 20 days (range 3-62 days), 18 days (range 5-109 days) and 15 days (range 4-53 days) in Groups 1 to 3 respectively. Anti-coagulation achieved the targeted international normalized prothrombin ratio (INR) and anti-factor Xa levels consistent with effective in vivo therapy yet, no significant impact on median xenograft function was observed. At rejection, a similar histology of thrombosis and ischemia was apparent in each group and the levels of fibrin deposition and platelet thrombi in rejected tissue was the same. Anti-coagulation with warfarin or LMWH did not have a significant impact on the onset of DXR and microvascular thrombosis. However, a role for specific anticoagulant strategies to achieve long-term xenograft function cannot be excluded.",
keywords = "Antibody, Anticoagulation, Cardiac, Non-Gal, Thrombosis, Xenotransplantation",
author = "Byrne, {Guerard W.} and Schirmer, {Johannes M.} and Fass, {David N.} and Teotia, {Sumeet S.} and Kremers, {Walter K.} and Hui Xu and Bashoo Naziruddin and Tazelaar, {Henry D.} and Logan, {John S.} and McGregor, {Christopher G A}",
year = "2005",
month = "5",
doi = "10.1111/j.1600-6143.2005.00792.x",
language = "English (US)",
volume = "5",
pages = "1011--1020",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function

AU - Byrne, Guerard W.

AU - Schirmer, Johannes M.

AU - Fass, David N.

AU - Teotia, Sumeet S.

AU - Kremers, Walter K.

AU - Xu, Hui

AU - Naziruddin, Bashoo

AU - Tazelaar, Henry D.

AU - Logan, John S.

AU - McGregor, Christopher G A

PY - 2005/5

Y1 - 2005/5

N2 - Microvascular thrombosis is a prominent feature in cardiac delayed xenograft rejection (DXR). We investigated the impact of warfarin or low-molecular-weight heparin (LMWH) anti-coagulation on xenograft function using a heterotopic pig-to-primate model. Donor hearts were from CD46 transgenic pigs and baboon immunosuppression included tacrolimus, sirolimus, anti-CD20 and TPC, an α-galactosyl-polyethylene glycol conjugate. Three groups of animals were studied. Group 1 (n = 9) was treated with warfarin. Group 2 (n = 13) with LMWH and Group 3, received no anticoagulant drugs. The median duration of xenograft function was 20 days (range 3-62 days), 18 days (range 5-109 days) and 15 days (range 4-53 days) in Groups 1 to 3 respectively. Anti-coagulation achieved the targeted international normalized prothrombin ratio (INR) and anti-factor Xa levels consistent with effective in vivo therapy yet, no significant impact on median xenograft function was observed. At rejection, a similar histology of thrombosis and ischemia was apparent in each group and the levels of fibrin deposition and platelet thrombi in rejected tissue was the same. Anti-coagulation with warfarin or LMWH did not have a significant impact on the onset of DXR and microvascular thrombosis. However, a role for specific anticoagulant strategies to achieve long-term xenograft function cannot be excluded.

AB - Microvascular thrombosis is a prominent feature in cardiac delayed xenograft rejection (DXR). We investigated the impact of warfarin or low-molecular-weight heparin (LMWH) anti-coagulation on xenograft function using a heterotopic pig-to-primate model. Donor hearts were from CD46 transgenic pigs and baboon immunosuppression included tacrolimus, sirolimus, anti-CD20 and TPC, an α-galactosyl-polyethylene glycol conjugate. Three groups of animals were studied. Group 1 (n = 9) was treated with warfarin. Group 2 (n = 13) with LMWH and Group 3, received no anticoagulant drugs. The median duration of xenograft function was 20 days (range 3-62 days), 18 days (range 5-109 days) and 15 days (range 4-53 days) in Groups 1 to 3 respectively. Anti-coagulation achieved the targeted international normalized prothrombin ratio (INR) and anti-factor Xa levels consistent with effective in vivo therapy yet, no significant impact on median xenograft function was observed. At rejection, a similar histology of thrombosis and ischemia was apparent in each group and the levels of fibrin deposition and platelet thrombi in rejected tissue was the same. Anti-coagulation with warfarin or LMWH did not have a significant impact on the onset of DXR and microvascular thrombosis. However, a role for specific anticoagulant strategies to achieve long-term xenograft function cannot be excluded.

KW - Antibody

KW - Anticoagulation

KW - Cardiac

KW - Non-Gal

KW - Thrombosis

KW - Xenotransplantation

UR - http://www.scopus.com/inward/record.url?scp=20244380021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244380021&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2005.00792.x

DO - 10.1111/j.1600-6143.2005.00792.x

M3 - Article

C2 - 15816881

AN - SCOPUS:20244380021

VL - 5

SP - 1011

EP - 1020

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 5

ER -